Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in the Skin of Food Allergy Patients
NCT06618963Phase 4Recruiting
- Sponsor
- National Jewish Health
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab in food allergy (2 arms), sponsored by National Jewish Health. Primary endpoints: Lipidomic analysis at 5 months, Metabolomic analysis at 5 months and 3 more. Started Oct 2024; status: recruiting.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT06618963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618963.